VT News
Kit Young

Kit Young

Ask VT AI
View News Summary
  • Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making its stock a top performer.
  • NFL rookies shine and struggle in preseason, with standout performances and devastating injuries impacting roster battles.
  • Analysts warn investors to be cautious of multiple risky stocks facing headwinds, including MicroStrategy and GameStop for reliance on volatile assets.
20 hours
USA flag

United States Politics

Discover the latest news, candidates, 
and key topics of US politics

Latest News
Ask VT AI
View News Summary
  • Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making its stock a top performer.
  • NFL rookies shine and struggle in preseason, with standout performances and devastating injuries impacting roster battles.
  • Analysts warn investors to be cautious of multiple risky stocks facing headwinds, including MicroStrategy and GameStop for reliance on volatile assets.
20 hours
USA flag

United States Politics

Discover the latest news, candidates, 
and key topics of US politics

Most Reported By
News from Kit Young

Top Topics

Trending in U.S.

World

Sport